Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells

World Journal of Gastroenterology

Volumn 10, Issue 13, 2004, Pages 1979-1983

  Yu, Zhi Wei ^a   Zhao, Peng ^a   Liu, Ming ^a   Dong, Xin Shu ^a   Tao, Ji ^a   Yao, Xue Qin ^b   Yin, Xin Hua ^a   Li, Yu ^a   Fu, Song Bin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; TETRAZOLIUM;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CLINICAL PRACTICE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TIME; WESTERN BLOTTING; WILD TYPE;

EID: 3543072934     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i13.1979     Document Type: Article

References (38)

1. Zhu XH, Li JY, Xia XM, Zhu MQ, Geng MJ, Chen L, Zhang JQ. Multidrug resistance mechanisms in cell line HL-60/VCR. Aizheng 2002; 21: 1310-1313
2. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 15-21
3. Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 2003; 42: 237-243
4. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310
5. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25: 1-6
6. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53: 587-596
7. Abu-Qare AW, Elmasry E, Abou-Donia MB. A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 2003; 6: 279-288
8. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165
9. Tullo A, D'Erchia AM, Sbisa E. Methods for screening tumors for p53 status and therapeutic exploitation. Expert Rev Mol Diagn 2003; 3: 289-301
10. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002; 99: 389-394
11. Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001; 283: 732-737
12. Yuan R, Meng Q, Hu H, Goldberg ID, Rosen EM, Fan S. P53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemother Pharmacol 2001; 47: 161-169
13. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-898
14. Yu ZW, Dong XS, Wang XH. The relationship between the mdrl gene expression and mutations of p53 gene and ras gene in colorectal cancer. Chin J Oncol 2002; 24: 480
15. Yao XQ, Qing SH, Yang Y. Establishment of multidrug-resistant human colorectal cancer cell line LoVo/5-FU: a preliminary study of biological characterization. J First Mil Med Univ 2001; 21: 19-21
16. Xu ZL, Mizuguchi H, Mayumi T, Hayakawa T. Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 2003; 309: 145-151
17. Mohr L, Geissler M. Gene therapy: new developments. Schweiz Rundsch Med Prax 2002; 91: 2227-2235
18. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, Neukam FW, Schneider H. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 2003; 10: 1089-1098
19. Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68: 203-206
20. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917
21. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526
22. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wide-type p53. Science 1990; 249: 912-915
23. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type p53 and mutant p53. FASEB J 1993; 7: 855-865
24. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355
25. Wolcke J, Reimann M, Klumpp M, Gohler T, Kim E, Deppert W. Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy: Evidence for different modes of high affinity DNA binding. J Biol Chem 2003; 278: 32587-32595
26. Sowa Y, Sakai T. Gene-regulating chemoprevention against cancer - as a model for "molecular-targeting prevention" of cancer. Nippon Eiseigaku Zasshi 2003; 58: 267-274
27. Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 1992; 6: 1143-1152
28. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17: 389-397
29. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462
30. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to conger differential responsiveness to wild-type p53 and mutant p53. Oncogene 1993; 8: 1529-1535
31. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. P53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997; 94: 11037-11042
32. Bush JA, Li G. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis 2002; 23: 1603-1607
33. Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol 1999; 19: 2594-2600
34. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ, Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 1992; 89: 12028-12032
35. Huang H, Kaku S, Knights C, Park B, Clifford J, Kulesz-Martin M. Repression of transcription and interference with DNA binding of TATA-binding protein by C-terminal alternatively spliced p53. Exp Cell Res 2002; 279: 248-259
36. Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem 1993; 268: 7923-7928
37. Liedtke C, Groger N, Manns MP, Trautwein C. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 2003; 278: 27593-27604
38. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, Puisieux A, Ann Jordan M, Dumontet C. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88: 1793-1799